Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Nano Dimension Ltd - ADR (NNDM) vs Revvity Inc (RVTY) Price & Performance

Nano Dimension Ltd - ADRTrade
Revvity IncTrade

Price performance (Past 24H)

Key statistics

Nano Dimension Ltd - ADR vs Revvity Inc — how do they compare? Nano Dimension Ltd - ADR trades at $1.55 (market cap $328.52M), while Revvity Inc trades at $154.18 (market cap $16.98B). The key difference: Revvity Inc is far larger — about 51.7× Nano Dimension Ltd - ADR's market cap, and Revvity Inc pays a 0.18% dividend while Nano Dimension Ltd - ADR pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nano Dimension Ltd - ADR for 43 Days and Revvity Inc for 12 Days on average.

NNDMRVTY
Market Cap
$328.52M$16.98B
Volume
1,160,9451,456,900
Sector
TechnologyHealth
52-Week High
$2.14$157.36
52-Week Low
$1.21$82.26
Typical Hold Time
43 Days12 Days
Enterprise Value
-$76.33M$19.30B
Dividend Yield
—0.18%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Nano Dimension Ltd - ADR

Nano Dimension (NNDM) trades at $1.56, up 0.65% with a bearish technical signal. The company shows revenue growth from $102M in 2025 to $121M in 2026 but remains unprofitable with a -135% net margin. Recent strategic actions include cost-cutting initiatives and board changes, with cash reserves of $758M providing operational runway despite negative cash flows.

The outlook remains challenging with persistent losses and negative cash flow, though valuation ratios appear attractive with P/S of 2.73 and P/B of 0.68. Key risks include execution of turnaround strategy and competitive pressures in the industrial 3D printing sector. Analyst sentiment is cautious given the company's ongoing restructuring efforts.

Revvity Inc

Revvity (RVTY) trades at $154.18, up 0.38% today and near its 52-week high of $158.28. The stock shows a bullish technical trend with strong moving averages and has beaten earnings estimates for the last three quarters. Recent developments include the launch of a new diabetes screening kit in Europe and the acquisition of Human Cell Design to expand its metabolic disease research tools. Revenue remains stable around $2.9 billion, though net income margin is modest at 8.16%.

The outlook is positive with analyst consensus leaning buy (51.72%) and a price target of $132.13, though the current price exceeds it. Key opportunities include diagnostic growth and AI-driven demand, while risks involve premium valuation (P/E 73.15), margin pressures, and exposure to China market volatility. Earnings on November 3, 2026, will be critical for near-term direction.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

NNDM

No sentiment data available yet.

RVTY
0% Buy100% Sell
Avg holding period · 12 Days

Top news

Latest headlines on both assets

About Nano Dimension Ltd - ADR

Nano Dimension Ltd is engaged in research and development of a three-dimensional printer that prints electronic circuit boards, also known as printed circuit boards, and ink materials and products based on nanotechnology. Its products consist of two main product lines - Dragonfly 2020 3D printer and proprietary ink products. The company's Dragonfly 2020 3D printer currently in development uses proprietary ink and integrated software to quickly create fully functioning PCB prototypes. Geographically, it generates maximum revenue from the USA followed by the Asia Pacific and Europe and Israel. It serves the Commercial, Research and Printing services industries.

Read more on NNDM →

About Revvity Inc

Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.

Read more on RVTY →